ABL Diagnostics: Information Relating to the Total Number of Voting Rights and the Number of Shares Constituting the Share Capital
(Articles L. 233-8, II of the French Commercial Code and 223-16 of the AMF General Regulation)
Regulatory News:
ABL Diagnostics: (Paris:ABLD)
|
Date |
Total Number of Shares Constituting the Share Capital |
Number of Voting Rights (1) (2) |
|
|
Theoretical Voting Rights |
Exercisable Voting Rights |
||
|
August 12, 2026 |
16 114 656 |
30.501.420 |
30.471.564 |
|
(1) Theoretical voting rights are calculated on the basis of all shares to which voting rights are attached, including shares for which voting rights have been suspended or deprived. (2) In accordance with the resolutions adopted on March 23, 2022, double voting rights are granted to all fully paid-up shares that have been registered in the name of the same shareholder for at least two years, effective from March 23, 2022. |
|||
About ABL Diagnostics (ABLD)
ABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:
- Molecular polymerase chain reaction (PCR) detection – UltraGene, and
- Genotyping by DNA sequencing – DeepChek®.
ABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.
Following the acquisition of TEXCELL’s operations, ABL Diagnostics is expanding its activities in the life sciences sector by integrating expertise and services dedicated to virology, biosafety testing and biopharmaceutical development support.
ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.
An expanding portfolio of microbiology products:
- HIV – Drug resistance testing, including a whole genome kit.
- SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced Detection Solutions.
- Microbiome and taxonomy – 16s/18s RNA-based analyses.
- Other viral and bacterial targets – Comprehensive molecular assays.
Integrated Solutions
- Real-time syndromic PCR tests
- Nadis® – Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis.
ABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.
Public limited company with a capital of €1,611,465.60 Registered office: 72C route de Thionville - 57140 WOIPPY 552 064 933 R.C.S. METZ
View source version on businesswire.com: https://www.businesswire.com/news/home/20260827980022/en/
ABL Diagnostics SA Société anonyme au capital de 1 611 465,60 euros Headquarters : 72C route de Thionville - 57140 WOIPPY 552 064 933 R.C.S. METZ
Tel : +33 (0)7 83 64 68 50 Email : info@abldiagnostics.com https://www.abldiagnostics.com/